These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38113781)

  • 1. Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder.
    Tyler J; Gallagher T; Wheaton MG; Hamlett GE; Rosenfield B; Rosenfield D; Simpson HB; Foa EB
    J Anxiety Disord; 2024 Jan; 101():102805. PubMed ID: 38113781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
    Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D
    JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive-compulsive disorder.
    Maher MJ; Huppert JD; Chen H; Duan N; Foa EB; Liebowitz MR; Simpson HB
    Psychol Med; 2010 Dec; 40(12):2013-23. PubMed ID: 20416137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
    McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
    J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.
    Wheaton MG; Gershkovich M; Gallagher T; Foa EB; Simpson HB
    Depress Anxiety; 2018 Mar; 35(3):256-263. PubMed ID: 29394511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
    Zandberg LJ; Zang Y; McLean CP; Yeh R; Simpson HB; Foa EB
    Behav Res Ther; 2015 May; 68():76-81. PubMed ID: 25824533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder.
    Grant JE; Mancebo MC; Weinhandl E; Odlaug BL; Eisen JL; Rasmussen SA
    Int Clin Psychopharmacol; 2013 Jul; 28(4):200-5. PubMed ID: 23587985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.
    Foa EB; Simpson HB; Liebowitz MR; Powers MB; Rosenfield D; Cahill SP; Campeas R; Franklin M; Hahn CG; Hembree EA; Huppert JD; Schmidt AB; Vermes D; Williams MT
    J Clin Psychiatry; 2013 May; 74(5):464-9. PubMed ID: 23759449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive-compulsive disorder.
    Park CI; Kim HW; Jeon S; Hwang EH; Kang JI; Kim SJ
    Psychopharmacology (Berl); 2020 Nov; 237(11):3489-3496. PubMed ID: 32748029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of treatment on quality of life and functioning in OCD.
    Asnaani A; Kaczkurkin AN; Alpert E; McLean CP; Simpson HB; Foa EB
    Compr Psychiatry; 2017 Feb; 73():7-14. PubMed ID: 27838572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.
    Simpson HB; Liebowitz MR; Foa EB; Kozak MJ; Schmidt AB; Rowan V; Petkova E; Kjernisted K; Huppert JD; Franklin ME; Davies SO; Campeas R
    Depress Anxiety; 2004; 19(4):225-33. PubMed ID: 15274171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.